The family of weight-loss jabs known as GLP-1 agonists are among pharma’s biggest blockbusters. But drugs like Ozempic have the potential to do much more than tackle diabetes and obesity. They have been found to treat cardiovascular and kidney disease, and they are also being tested for liver disease, Alzheimer’s and even addiction. If they live up to their promise, GLP-1s are set to transform health care. How can one class of drug do so much?

Host: Alok Jha, The Economist’s science and technology editor. Contributors: Caroline Messer, an endocrinologist in New York; Daniel Drucker of the University of Toronto; and The Economist’s Natasha Loder and Shailesh Chitnis. 

For more on this topic, listen to our podcast on the physiological and psychological causes of obesity—and why GLP-1 drugs could reshape the world.

Transcripts of our podcasts are available via economist.com/podcasts.

Listen to what matters most, from global politics and business to science and technology—subscribe to Economist Podcasts+.

For more information about how to access Economist Podcasts+, please visit our FAQs page or watch our video explaining how to link your account.